A multicenter, randomized, double-blind, double-simulated, positive-controlled phase III clinical trial comparing the efficacy and safety of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation (SalmexTM) with Seretide in adult subjects with bronchial asthma

开始日期2020-07-01

申办/合作机构

广州医科大学附属第一医院（广州呼吸中心）

NCT03543176

/ CompletedN/A

Claims-linked Survey Study to Assess Burden of Illness Among Patients Treated With LAMA/LABA vs ICS/LABA Single Inhaler Dual Therapy

The main purpose of the study is to assess the burden of illness for, COPD using both patient-reported symptom burden and claims-based economic burden, among the subjects treated with single-inhaler dual therapy treatments, Fluticasone/Salmeterol FLUT/SAL; Advair) or Umeclidinium/Vilanterol (UMEC/VI; Anoro) to support Global Initiative for Chronic Lung Disease (GOLD) category B recommendations. The study will use a health plan recruitment strategy and subject's will be recruited using Optum's health plan recruitment strategy to collect information relating to the subject's condition history, current treatment, smoking history, symptoms and symptom severity (Modified Medical Research Council Dyspnoea Scale [mMRC] and COPD Assessment Test [CAT]), and demographic and sociodemographic characteristics. A total of 2700 subject's, are planned to be enrolled in the study to reach the target evaluable sample size, n=770 subjects. Following completion of data collection, results of the survey, will be merged with claims data, covering the 12-month Baseline period for analysis. Pharmacy and medical claims data, will be used to calculate all-cause and COPD-related health care utilization and costs, treatment patterns, and Baseline clinical characteristics. The study duration is estimated to be of 12-months.

开始日期2018-05-31

申办/合作机构

GSK Plc

[+1]

100 项与 AL-209 相关的临床结果

登录后查看更多信息

100 项与 AL-209 相关的转化医学

登录后查看更多信息

100 项与 AL-209 相关的专利（医药）

登录后查看更多信息

2,335

项与 AL-209 相关的文献（医药）

2025-09-01·COLLOIDS AND SURFACES B-BIOINTERFACES

A triple-cascade nanoreactor for potent anti-tumor chemodynamic and immunotherapy

Article

作者: Zhang, Yanyan ; Zhu, Li-Min ; Yin, Hang ; Li, Fan ; Wang, Tong ; Williams, Gareth R ; Wu, Junzi ; Liu, Yang ; Du, Yichao ; Xu, Jianxiang ; Zheng, Yilu

Chemodynamic therapy (CDT) has shown promising effects in the treatment of malignant tumors, especially in inducing immunogenic cell death (ICD). However, the therapeutic efficacy of CDT is much weakened due to limitations in tumor oxidative stress response, and intracellular H₂O₂ and catalyst levels. In order to solve these challenges, we have designed an intracellular acid-activated cascade nanoreactor (Sal/Fe₃O₄@SiO₂-NaCN) which induces ICD by accelerating the process of CDT-mediated ferroptosis. The nanoreactor operates in three synergistic steps. Firstly, the platform can catalyze the degradation of glucose to gluconic acid and H₂O₂ under ultrasound (US) exposure in an acidic environment. Secondly, Fe₃O₄ can then convert this H₂O₂ to ·OH. In addition, salinomycin (Sal) causes Fe accumulation in the cell and enhances the efficacy of the Fenton process. Extensive in vitro and in vivo experiments reveal the production of reactive oxygen species, accumulation of Fe in cells, and stimulation of ferroptosis and ICD. In a bilateral tumor model, magnetic resonance signals and excellent therapeutic effects were observed in vivo. This novel nanoreactor offers a promising strategy for CDT-based cancer treatment and immunotherapy.

2025-09-01·POULTRY SCIENCE

Compound of Lactobacillus reuteri and Candida rugosa supplementation alleviates intestinal barrier lesion via improving the gut microbiota in broilers infected with Salmonella Typhimurium

Article

作者: Fang, Haiyan ; Yang, Xiaoran ; Hu, Dan ; Pan, Li'an ; Ni, Yingdong ; Wang, Kuanbo ; Chen, Pengnan

As a common zoonotic pathogen, Salmonella Typhimurium (S. Typhimurium) impairs the growth performance of broilers and also poses a threat to public health through the food chain. Probiotics as a kind of green microecological agents have been widely used to improve intestinal health. This study investigated the protective effect of combined use of Lactobacillus reuteri (L. reuteri) and Candida rugosa (C. rugosa) on reducing S. Typhimurium infection in broilers. A total of 144 one-day-old Arbor Acres (AA) broilers were randomly assigned to four groups: control (Con) group fed with a basal diet, Salmonella (Sal) group injected intraperitoneally with S. Typhimurium, antibiotic treatment (Sal+Ant) group, and probiotics supplementation (Sal+Pb) group. Combined probiotics were supplemented via drinking water from hatching throughout the experiment. S. Typhimurium was challenged at d 15, and samples were collected at 4 days later. Results showed that as antibiotic treatment, probiotics supplementation significantly improved body weight (BW), feed conversion ratio (FCR), and organ edema of broilers compared to Sal group (P < 0.05). Histological analysis of the ileum revealed that broilers in Sal+Pb group had higher villus height (VH) and crypt depth (CD), but lower histopathological score compared to Sal group (P < 0.05). Feeding probiotics compound also ameliorated the decrease of both mucus thickness and the number of goblet cells (GCs) induced by S. Typhimurium infection, consistent with the upregulation of MUC2 gene expression (P < 0.05) in the ileal mucosa. Furthermore, the colonization of Salmonella was also decreased in Sal+Pb group, accompanied with downregulation of pro-inflammatory cytokines genes expression (e.g., TNF-α, IL-1β) and upregulation of anti-inflammatory cytokine genes expression (e.g., IL-10) (P < 0.05) in the ileum. 16S rRNA sequencing showed that probiotics supplementation mitigated the Salmonella-induced decline in Bacteroides abundance, which exhibited positive correlations with cecal expression of anti-inflammatory cytokines (TGF-β, IL-10) and barrier-related genes (MUC2, ZO-1, ZO-2, Occludin) (P < 0.05). However, the increased abundances of Campylobacter and Escherichia-Shigella in the Sal group showed positive correlations with the relative weight of liver, heart and spleen to BW, but had negative correlations with BW and cecal expression of IL-10, MUC2, ZO-1, Occludin. (P < 0.05). These results indicate that combined use of L. reuteri and C. rugosa can greatly alleviate the gut injury induced by Salmonella infection through increasing mucin production, inhibiting pro-inflammatory cytokines and remodeling gut microbiota composition, and finally improve growth performance of broilers.

2025-09-01·AQUATIC TOXICOLOGY

From pharmaceuticals to toxic threats: Unveiling the impact of furosemide and by-products on fish model

Article

作者: Duval, Aliénor ; Garrigue-Antar, Laure ; Sandré, Fidji

Pharmaceutical pollutants and their transformation products pose emerging challenges to aquatic ecosystems. Among these, furosemide (FUR), a widely used diuretic, has gained attention due to the potential ecological risks of its degradation products, saluamine (SAL) and pyridinium (PYR). This study investigates the sub-lethal effects of SAL and PYR on zebrafish larvae (Danio rerio), focusing on oxidative stress, cardiac function, and behavioral responses at environmentally relevant concentrations. Our results reveal that both SAL and PYR induce significant reactive oxygen species (ROS) production, leading to oxidative stress dysfunction. Cardiovascular analyses show marked alterations in heart rate, while behavioral assays demonstrate impaired locomotion, even at low exposure levels concentrations consistent with those detected in natural water bodies. Importantly, these effects were observed at concentrations where FUR itself showed no significant impact, emphasizing the greater toxicity potential of its degradation products. These findings underscore the need to incorporate pharmaceutical transformation products into environmental risk assessments and regulatory frameworks, as they may exert greater ecological threats than their parent compounds. Future studies are required to better elucidate the long-term and multi-trophic impacts of these pollutants on aquatic ecosystems.

100 项与 AL-209 相关的药物交易

登录后查看更多信息